Semin Neurol 2019; 39(05): 589-595
DOI: 10.1055/s-0039-1693005
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Guillain–Barre Syndrome

Elia Malek
1  Department of Neurology, American University of Beirut Medical Center, Riad El Solh, Beirut, Lebanon
,
1  Department of Neurology, American University of Beirut Medical Center, Riad El Solh, Beirut, Lebanon
› Author Affiliations
Further Information

Publication History

Publication Date:
22 October 2019 (online)

Abstract

Guillain–Barre syndrome (GBS) is the leading cause of acute paralysis that can potentially affect all of the human population. GBS is believed to be an immune-mediated disease, possibly triggered by a recent infection, and driven by an immune attack targeting the peripheral nervous system. GBS can be divided into several subtypes depending on the phenotype, pathophysiology, and neurophysiological features. Unfortunately, morbidity and mortality rates are still high despite the current understanding of the pathophysiology and available treatment options. Additional research is still needed to shed more light into the pathogenesis for a better understanding and treatment of this condition.